| 1. |
- Brown, John, et al.
(author)
-
Exploring the electrochemistry of PTCDI for aqueous lithium-ion batteries
- 2024
-
In: Energy Storage Materials. - 2405-8297. ; 66:103218
-
Journal article (peer-reviewed)abstract
- Aqueous lithium-ion batteries (ALIBs) hold promise of providing cost-effective and safe energy storage in the context of an increasingly environmentally aware narrative. Moreover, mitigating concerns surrounding the critical raw materials present in traditional LIBs reinforces the alignment with such ideals. Herein, we delve into the electrochemistry of perylene-3,4,9,10-tetracarboxylic acid diimide (PTCDI) and evaluate its potential as an organic anode active material for ALIBs. We find the all-organic anode to reversibly (de)intercalate Li+ with moderately concentrated aqueous electrolytes, although in a slightly different manner compared with organic solvents. Furthermore, the half-cell electrochemical performance in terms of capacity, capacity retention, rate performance, Coulombic efficiency, and self-discharge, is all indeed satisfactory, where proof-of-concept ALIBs using the high voltage lithium manganese oxide (LMO) exhibit >70 Wh kg−1(PTCDI+LMO) and an average voltage of ca. 1.5 V. These findings have the intention to further encourage organic redox-active material R&D with more dilute aqueous electrolytes, potentially paving the way towards a greener and more sustainable energy landscape.
|
|
| 2. |
- Bock, Thomas, et al.
(author)
-
Proteomic Analysis Reveals Drug Accessible Cell Surface N-Glycoproteins of Primary and Established Glioblastoma Cell Lines
- 2012
-
In: Journal of Proteome Research. - : American Chemical Society (ACS). - 1535-3893 .- 1535-3907. ; 11:10, s. 4885-4893
-
Journal article (peer-reviewed)abstract
- Glioblastoma is the most common primary Glioblastoma Cell Surface Capturing brain tumor in adults with low average survival time after diagnosis. In order to improve glioblastoma treatment, new drug-accessible targets need to be identified. Cell surface glycoproteins are prime drug targets due to their accessibility at the surface of cancer cells. To overcome the limited availability of suitable antibodies for cell surface protein detection, we performed a comprehensive mass spectrometric investigation of the glioblastoma surfaceome. Our combined cell surface capturing analysis of primary ex vivo glioblastoma cell lines in combination with established glioblastoma cell lines revealed 633 N-glycoproteins, which vastly extends the known data of surfaceome drug targets at subcellular resolution. We provide direct evidence of common glioblastoma cell surface glycoproteins and an approximate estimate of their abundances, information that could not be derived from genomic and/or transcriptomic glioblastoma studies. Apart from our pharmaceutically valuable repertoire of already and potentially drug-accessible cell surface glycoproteins, we built a mass-spectrometry-based toolbox enabling directed, sensitive, and repetitive glycoprotein measurements for clinical follow-up studies. The included Skyline Glioblastoma SRM assay library provides an elevated starting point for parallel testing of the abundance level of the detected glioblastoma surfaceome members in future drug perturbation experiments.
|
|
| 3. |
|
|
| 4. |
|
|
| 5. |
|
|
